Biotech News
Paratek Pharmaceuticals Announces Positive Top-line Efficacy and Safety Data from Post-Marketing Study of NUZYRA® (omadacycline) for Patients with Moderate to Severe Community-Acquired Bacterial Pneumonia
Met all Primary and Secondary Efficacy Endpoints and Was Generally Safe and Well-Tolerated
Largest Clinical Data Set in Pneumonia for Any Antibiotic Approved in the Last Decade
Label Update Discussions with FDA to Begin as Early...